Related Experiment Videos
Small-duct primary sclerosing cholangitis: a long-term follow-up study
Paul Angulo1, Yaakov Maor-Kendler, Keith D Lindor
1Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Hepatology (Baltimore, Md.)
|May 25, 2002
Summary
Small-duct primary sclerosing cholangitis (PSC) is a distinct condition in inflammatory bowel disease patients with a better long-term prognosis than classic PSC. Some patients may progress to advanced liver disease.
Area of Science:
- Hepatology
- Gastroenterology
- Inflammatory Bowel Disease Research
Background:
- Some inflammatory bowel disease (IBD) patients exhibit chronic cholestasis and liver histology suggestive of primary sclerosing cholangitis (PSC) despite normal cholangiography.
- These patients, diagnosed with small-duct PSC, have been understudied, necessitating research into their prevalence and long-term outcomes.
Purpose of the Study:
- To investigate the prevalence of small-duct PSC among patients with sclerosing cholangitis.
- To determine the long-term clinical outcomes and prognosis of patients diagnosed with small-duct PSC.
Main Methods:
- A retrospective study matching 18 small-duct PSC patients with 36 classic PSC patients by age and sex.
- Follow-up data spanning up to 32.5 years, including subsequent cholangiography, malignancy development, and liver transplantation or death.
Main Results:
- Small-duct PSC constituted 5.8% of all sclerosing cholangitis cases.
- Three of five small-duct PSC patients progressed to classic PSC on follow-up cholangiography.
- Small-duct PSC patients had significantly better survival free of liver transplantation compared to classic PSC patients and similar survival to the general population.
Conclusions:
- Small-duct PSC may represent an early stage of PSC with a more favorable long-term prognosis.
- While many small-duct PSC patients experience better outcomes, a subset may progress to classic PSC or end-stage liver disease requiring transplantation.